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Abstract:   
Background: Cytokines regulate the expression of inflammatory molecules which destabilize 
the atheromatic plaques. This study focuses on studying the association of inflammatory 
cytokine polymorphisms like TNF-α -308 (G/A), TNF-β +252 (A/G), IL-6 -174 (G/C) and 
IL-6 -597 (G/A), and IFN-ɣ +874 (T/A) with coronary artery disease (CAD) among north 
Indian patients. 
Materials and methods: 143 CAD and 137 normal healthy controls were recruited in this 
study. DNA extraction was carried out by high salting out method. TNF-α -308 (G/A) 
(rs1800797), TNF-β +252 (A/G) (rs909253), IL-6 -174 (G/C) (rs1800795), IL6 -597 (G/A) 
(rs1800797), and IFN-ɣ +874 (T/A) (rs2430561) SNPs were genotyped by TaqMan®SNP 
genotyping assays. Different statistical analyses were performed using SPSS v 22.0 and 
SNPStats. p≤0.05 was considered significant.  
Results: Significant risk association with CAD was found for TNF-α -308 (G/A) “A” allele 
(OR =5.6, CI 1.8-17.4, p=0.001) and TNF-β +252 (A/G) “G” allele (OR=3.4, CI=1.9-6.0, 
p<0.001). However, no statistical significance was found for IL-6 -174 (G/C) or IL6 -597 
(G/A), with CAD. TNF-α -308 (G/A), and TNF-β +252 (A/G) haplotype “GG” “AG” 
increased CAD risk significantly (GG haplotype, adjusted OR = 2.6, CI 1.4-5.0, p=0.003 and 
AG haplotype OR =8.5, CI 2.2-33.35, p=0.002) after adjustments for age, sex, TC, TG, HDL, 
APOB, smoking and diet.  
Discussion: The present study found significant risk association for TNF-α -308 (G/A), and 
TNF-β +252 (A/G) genotypes, alleles and haplotypes, with CAD in a North Indian 
Population. 
  
Introduction  
Coronary artery disease (CAD) is a major cause of morbidity and mortality globally and has a 
complex developmental process with a number of contributing factors; gender, age, 
inflammation, hypertension, hypercholesterolemia, diabetes, obesity, tobacco smoking, 
alcohol drinking, total cholesterol and LDL cholesterol (Hansson, 2005;Yiannakouris et al., 
2014). However, not all individuals who are exposed to the same risk factors of CAD 
necessarily develop disease, which suggests that inherited genetic factors contribute to the 
underlying pathogenesis of CAD. Indians are among the populations with the highest 
susceptibility and have an alarmingly high incidence of CAD (Enas & Senthilkumar, 2001). 
In addition to traditional CAD risk factors, strict endogamous marital patterns, rapid 
urbanisation and decreases in physical activity are some of the additional factors driving 
rampant increases in CAD among Indian populations. However, even all the risk factors 
taken together do not fully explain the complexity or the magnitude of disease burden (Anand 
et al., 2000). Thus genetic factors should be comprehensively and systematically studied in 
different populations of the Indian Subcontinent. 
Inflammation plays a central role in atherosclerosis development and other manifestations of 
CAD (Hansson, 2005; Zakynthinos and Pappa, 2009). The underlying pathological 
mechanism of CAD is atheroma plaque instability, which is characterized by chronic 
inflammation caused by oxidized lipids adherent to the inner layer of the arterial wall. While 
the molecular mechanisms involved in the pathogenesis of CAD are still being de-convoluted 
(Libby at al., 2011) there is a consensus that the main events of unstable angina and 
myocardial infarction are due to the involvement of major inflammatory cytokines.  
Cytokines are produced in a variety of tissues and regulate the expression of a number of 
other inflammatory molecules which can lead to destabilization and finally rupture of 
vulnerable atheromatic plaques.   Several lines of evidence indicate that increased 
inflammatory cytokine levels and inflammatory cytokine activity detectable in peripheral 
blood have a prognostic role in predicting future cardiac events and clinical course (Tousoulis 
et al., 2006; De Gennaro et al., 2012). Recent studies have also shown that inflammation-
related genes might be correlated with  CAD risk (Zakynthinos  and  Pappa, 2009; Shankar 
and Kakkar 2010; Li et al., 2012; Xie et al., 2012; Singh et al., 2014), thus aligning a number 
of inflammatory cytokines, their expression and their activity, as key mediators of CAD. 
Inflammatory pathways are mediated by proximal cytokines, such as Tumor Necrosis Factor-
Alpha (TNF-α) and Tumour Necrosis Factor Beta (TNF-β)/Lymphotoxin Alpha) (LT-α), 
Interferon gamma (IFN-ɣ) and interleukin-6 (IL-6) which suggest they may influence CAD 
risk. However, multiple pro-inflammatory and anti-inflammatory cytokines may be involved 
in the pathogenesis of CAD having overlapping, antagonistic and synergistic effects.  
Tumor Necrosis Factor-α (TNF- α) and Tumour Necrosis Factor-β (TNF-β)/Lymphotoxin 
Alpha) (LT-α) 
TNF-α, is a pleiotropic pro-inflammatory cytokine of 233 amino-acids, which is encoded by 
TNF-α gene on chromosome 6p21 falling within the major histocompatibility complex (MHC) 
cluster on chromosome 6. It is generated by activated macrophages and facilitates the 
recruitment and infiltration of macrophages/monocytes into the sub-endothelium of arteries 
and contributes to the reduction of lipoprotein lipase activity. Elevated TNF-α levels have 
consistently been reported in patients with heart failure and increasing concentrations of the 
cytokine are related to the severity of CAD and mortality rate in patients. Different 
polymorphisms of the TNF-α gene may also lead to variation in the plasma level of TNF-α as 
there are several single nucleotide polymorphisms (SNPs) both within the gene and its 
promoter region. There have been significant susceptible/positive associations reported 
between TNF-α -308 (G/A) locus and CAD however other studies failed to find associations 
(Banerjee et al 2009; Bhanushali and Das 2013; Elahi et al., 2009; Garg et al., 2013; Wang et 
al., 2015). 
Lymphotoxin-alpha (LTA) also known as TNF beta (TNF-β), is another pro-inflammatory 
cytokine which plays an important role in the immunologic response. The LTA gene, like the 
TNF-α gene, is also located within the tumour necrosis factor (TNF) gene cluster in the MHC 
region on chromosome 6 at position 6p21.3. TNF-β has been linked in a number of studies to 
the intensity and duration of local inflammation with TNF-β +252 (A/G) correlating with the 
altered production of TNF-β (Messer et al., 1991). In contrast to TNF-α there are only a few 
studies on the role of TNF-β in CAD and the paucity of data is especially limiting on Indian 
populations (Garg et al., 2013). 
Interleukin-6 
Interleukin-6 (IL-6) is another pro inflammatory and immunoregulatory cytokine which has a 
significant role in the development of CAD. IL-6 up-regulates the synthesis of the acute 
phase proteins involved in the process of inflammation (Gleeson et al., 2011). IL-6 consists 
of 184 amino acid residues and is located on chromosome 7 at 7p21–p24. A common G/C 
polymorphism in the promoter region (−174 base pairs) affects promoter function and is 
associated with differences in plasma IL-6 levels (Fishman et al., 1998). While total IL-6 
expression may regulate the magnitude of inflammation and its correlation with CAD 
(Martins et al., 2006; Woo and Humphries, 2013) the IL-6 -174 (G/C) polymorphism has 
been associated with CAD (meta-analysis, GG vs. CC OR =0.80, CI 0.65-98, p=0.03,  Yang 
et al., 2013). In addition some other polymorphisms in this gene promoter region (-572G/C 
and -597G/A) are also predictors of the cytokine concentrations in plasma following 
inflammatory stimulus. These polymorphisms may influence CAD susceptibility by altering 
gene regulation and protein expression (Elahi et al., 2009; Woo and Humphries, 2013). Some 
studies show that IL6 polymorphisms are significantly increase the risk for CAD in different 
populations, but results are inconsistent and conflicting (Banerjee et al., 2009; Bhanushali 
and Das, 2013; Cui et al., 2013; Elahi et al., 2009; Mishra et al., 2013; Satti et al., 2013; Hou 
et al., 2015). 
Interferon gamma (IFN-γ) 
Interferon gamma (IFN-γ) is a pleiotropic soluble cytokine with antiviral and anti-tumour 
properties and its levels are elevated in unstable angina and myocardial infarction (Pasqui et 
al., 2006). The IFN- γ gene is located on chromosome 12q24.1, within this region, a SNP at 
position +874 (in the 1st intron) of the IFN-γ gene (rs2430561) maps to a putative nuclear 
factor-κB (NF-κB) binding site. This polymorphism (T allele) correlates with a higher 
production of IFN-γ and is associated with disease severity in different autoimmune and 
inflammatory diseases (Pacheco et al., 2008, Kohr at al., 2011) an example being the positive 
association of the T allele with CAD in an Indian population (OR =1.53, CI 1.10-2.13, 
p=0.01) (Garg et al., 2013).   
As there are few studies focusing on the role of inflammatory cytokines in CAD specifically 
in Indian populations (Banerjee et al., 2009; Bhanushali and Das, 2013; Garg et al., 2013; 
Mishra et al., 2013) this study was designed to explore the roles of TNF-α -308 (G/A), TNF-β 
+252 (A/G), IL-6 -174 (G/C) and IL6 -597 (G/A), and IFN-ɣ +874 (T/A) polymorphisms in a 
North Indian CAD population. This study was designed to contribute to the knowledge of 
population specific genetic risk factors which might improve prediction of CAD risk in 
Indian populations. 
Study population and Methods 
The study population consisted of 137 healthy controls and 143 patients with clinically 
diagnosed CAD, from Uttar Pradesh, North India (achieving a Quanto predicted sample size 
of 130 (http://biostats.usc.edu/Quanto.html) to achieve an odds ratio of 1.75 and statistical 
power above 80% using previously determined allele frequencies and odds ratios where 
available (Banerjee et al., 2009; Bhanushali and Das, 2013; Garg et al., 2013)).    
Patients were classified on the basis of at least 50% or more stenosis in one or more coronary 
arteries verified through coronary angiography. The healthy controls had no known history of 
ischemic heart disease, hypertension, diabetes, endocrine or metabolic disorders and were 
selected after administration of a treadmill exercise test to exclude the possibility of the 
patients having an underlying CAD (Rai et al., 2012). The DNA samples were collected with 
full written consent and the study protocol was approved by ethics committees of the 
SGPGIMS, Lucknow and Loughborough University. All recruitment and analyses followed 
the principles of Helsinki declaration.  
Clinical data was gathered on age, gender, diet (vegetarian vs. non-vegetarian), smoking-
status and lipid profiles (plasma total cholesterol (TC), triglycerides (TG), high density 
lipoproteins (HDL), low density lipoproteins (LDL), very low density lipoproteins (VLDL) 
and apolipoprotein B (ApoB). DNA extraction was performed using the salting out method 
(Sambrook and Russell, 2006) and genotyping of the TNF-α -308 (G/A) (rs1800629), TNF-β 
+252 (A/G) (rs909253), IL-6 -174 (G/C) (rs1800795) and IL6 -597 (G/A) (rs1800797) and 
IFN-ɣ +874 (T/A) (rs2430561) polymorphisms were performed using TaqMan®SNP 
Genotyping Assays. Genotypes were scored directly by viewing the presence or absence of 
fluorescence peaks using the StepOne TM Software v.2.3 (Applied Biosystems). Overall 
genotyping success rates varied from 94% for IL6 -597 (G/A) (rs1800797) to 99% for TNF-α 
-308 (G/A), (rs1800629). Failures were primarily due to DNA storage degradation and 
quality issues with 10% of the sample randomly repeated to test the reliability of genotyping 
the results of which indicate 100% concordance at all SNPs. 
Statistical analysis was carried out using the software packages EXCEL (Microsoft® ) and 
SPSS v 22.0 (SPSS Inc., Chicago, IL, US).). The patient and control databases were both 
assessed for Hardy-Weinberg Equilibrium (HWE) by calculating a chi-square value. 
Association statistics like odds ratios (OR) associated confidence intervals and p values were 
calculated using online programme SNPSTATs (http://bioinfo.iconcologia.net/SNPstats) 
(Solé et al., 2006). Clinical and life style parameters were analysed using t-tests and where 
required Kruskal-Wallis test. A p-value ≤ 0.05 was considered statistically significant. 
SNPstats programme was also used for adjustments for various clinical and demographic 
parameters (age, TC, TG, HDL, LDL, VLDL, APOB) and calculation of linkage 
disequilibrium and construction of haplotypes. 
Results 
Clinical parameters 
In the present sample, a statistically significant difference in Age, TC, TG, LDL, VLDL, and 
APOB was observed between CAD patients and controls. The patient cohort were older by 
nearly 4.5 years and as expected patients had higher levels of lipids (Table 1). 
Genotype and allele frequency distribution 
The genotype (number, percentage), and allele frequencies (with Standard errors (SE)) of the 
studied samples were in Hardy Weinberg Equilibrium (HWE) (Table 2). HWE was 
maintained for all the loci both in patients and controls except IFN-ɣ +874 (T/A) in controls 
(p=0.001) where there was an excess of homozygote genotypes and deficiency of 
heterozygotes. The crude association analysis showed that at TNF-α -308 (G/A) locus, AG 
genotype (OR =5.3, CI 2.0-14.4, p=0.0004), and A allele (OR =5.4, CI 2.0-14.5, p=0.0001) 
were significant susceptible contributors to CAD in this population (Table 2). These positive 
associations became stronger (AG genotype OR =5.5 CI 1.7-17.3, p =0.005 and A allele OR 
=5.6, CI 1.8-17.4, p<0.001) when adjusted for age, sex, TC, TG, HDL, APOB, smoking and 
diet. At this locus, all p values remained significant even after Bonferroni correction.  
At TNF-β +252 (A/G) locus, GG genotype (OR = 4.7, CI 1.5-15.2, p <0.0001)   and G allele 
(OR = 3.1, CI 2.0-4.9, p <0.0001) were positively associated with the CAD in this population. 
After adjusting for age, sex, TC, TG, HDL, APOB, smoking and diet, these odds ratios 
remained significant and improved in all models (e.g. GG OR = 6.3, CI 1.5-25.9, p<0.0001 
and G allele OR = 3.4, CI 1.9-6.0, p<0.0001). All genotypes containing G allele remained 
significant following Bonferroni corrections except for the recessive model. 
Both IL-6 (IL6 -174 (G/C) and IL6-597 (G/A)) loci showed no statistically significant 
association with CAD in any model or combination. The IFN-ɣ +874 (T/A) locus showed 
risk association (OR=1.8, CI=1.0-3.1) at co-dominant (AT vs AA) and over-dominant (AT vs 
AA+TT; OR=1.7, CI=1.1-2.8) models which became insignificant when adjusted for age, sex, 
TC, TG, HDL, APOB, smoking and diet. Other genotype combinations and models were 
statistically non-significant. A caution is warranted in interpretation of the results at IFN-ɣ 
+874 (T/A) locus as controls showed departure from HWE.  
Haplotype frequency 
Haplotype analysis was carried out at TNF-α -308 (G/A), TNF-β +252 (A/G), and IL-6 -174 
(G/C) and IL6 -597 (G/A) loci and results are presented in Table 3. TNF-α -308 (G/A), TNF-
β +252 (A/G) haplotypes  GG (crude OR =2.5, CI 1.5-4.1, p =0.0005) and AG (crude OR = 
7.8, CI 2.6-24.0, p =0.0003) increased the disease risk significantly even after the adjustments 
for age, sex, TC, TG, HDL, APOB, smoking and diet (GG haplotype OR =2.6, CI 1.4-5.0, p 
=0.003 and AG haplotype OR = 8.5, CI 2.2-33.4, p =0.002). At the IL6 gene (IL-6 -174 (G/C) 
and IL6 -597 (G/A)), no haplotype were significantly susceptible or protective.   
Interaction of SNPs with conventional CAD risk factors 
One way ANOVAs were carried out for genotypes and clinical parameters in both patients 
and controls to evaluate the contribution of genotypes to these intermediate phenotypes 
(Table 4). At TNF-α -308 (G/A) and TNF-β +252 (A/G) loci, there were no significant 
interactions between genotypes and age or lipid parameters. At other polymorphisms, there 
were some p values < 0.05 before the Bonferroni correction but these become non-significant 
after correction.  The IL-6 -174 (G/C) polymorphism is the only polymorphism showing 
highest number (3) interactions with TC, HDL, and LDL in control population before 
correction. 
Cross tabulations were carried out for genotypes and categorical variables (gender, diet and 
smoking habit) to explore interactions. In these analyses none of the results achieved 
statistical significance either in patients or controls. Contrary to our expectations, none of the 
inflammatory polymorphisms studied here interacted with smoking habits (results not 
presented but available). 
We also carried out binary logistic regression analysis (results not shown, but available) 
which confirmed that TNF-β +252 (A/G), age, two lipids; VLDL and APOB were 
independent contributors/predictors of CAD in this population. 
Discussion 
Genetic polymorphisms have an important role in the regulation of gene expression, and thus 
gene polymorphisms may contribute to the inter-individual differences in susceptibility, 
inception, progression and severity of disease. In this study we analysed five single 
nucleotide polymorphisms (SNPs) in four pro inflammatory genes (TNF-α -308 (G/A), TNF-
β +252 (A/G), IL-6 -174 (G/C) and IL6 -597 (G/A), and IFN-ɣ +874 (T/A)) using sensitive 
genotyping assays. The allele frequencies observed in controls were comparable to many 
populations of the Indian subcontinent and online databases (1000 genomes (IGSR); Garg et 
al., 2013; Mishra et al., 2013).   
In our study, TNF-α -308 (G/A), promoter region polymorphism was significantly associated 
with CAD, and this association remained significant in multivariate analysis, even after the 
adjustment with confounding variables (A allele OR= 5.6, CI 1.8-17.4, p=0.001). Minor 
allele A was more frequent in patients (9%) compared to controls (2%). Previous studies have 
produced inconsistent results for this locus among Indian populations (Banerjee et al., 2009; 
Bhanushali and Das 2013; Garg et al., 2013).  Bhanushali and Das (2013) did observe a 
positive association of TNF-α -308 (G/A) polymorphism with CAD (OR =3.37, CI 1.04-
11.54, p= 0.03), in crude analysis, but it was not significant when confounders were taken 
into consideration. Garg et al. (2013) analysed an endogamous group from Delhi (India) and 
showed no significant association of CAD (adjusted OR =1.08, CI 0.94-1.22, NS) with this 
polymorphism but found it to be associated with BMI. Banerjee and colleagues (2009) also 
did not find a significant association with CAD and this locus (OR =1.07, CI 0.64-1.81, p 
=0.79). Wang et al. (2015) using a meta-analysis approach showed TNF-α -308 (G/A), 
polymorphism is not associated with CAD in Indian populations (OR =1.24, CI 0.86-1.78, 
p=0.26) though there were only a limited number of Indian studies (6) included in this 
analysis with limited total sample size of 1698 cases and 1459 controls. Further investigations 
are therefore required to explore the role of this locus in CAD among Indian populations. 
TNF-β +252 (A/G), locus has not been extensively studied with reference to heart disease or 
CAD in global or Indian populations (Li et al., 2010; Gao et al., 2010; Garg et al., 2013). 
TNF-β +252 (A/G) odds ratios in the current CAD samples were highly significant in all 
models and remain significant after controlling for confounders (age, sex, TC, TG, HDL, 
APOB, smoking and diet) except in the recessive model. Garg et al. (2013) is the only study 
available on Indian populations for this locus and our results are consistent with their results 
though magnitude of effect is nearly 4 times higher in our study (e.g. AG vs. AA ORs 1.14 vs. 
4.6). This could be due to sampling of different population groups and geographical position 
of samples, though patient groups are of similar size.  This polymorphism was not associated 
with CAD in Chinese population or within a large meta-analysis (Gao et al., 2010, Li et al., 
2010).  As there are not many studies from India, it would be interesting to explore further if 
this is a regional/population specific disease effect.   
Haplotype analysis of TNF-α -308 (G/A) and TNF-β +252 (A/G) (LTA) (Table 3) confirmed 
that carrying the risk haplotype ‘AG’ increases the CAD by nearly 8 fold  and this remains 
significant even controlling for all other clinical variables. As control frequency for this 
haplotype is relatively low (0.014 compared to patients 0.093) caution is warranted in 
interpretations. 
Both IL-6 polymorphisms, (IL-6 -174 (G/C) (rs1800795) and IL-6 -597 (G/A), (rs1800797)) 
showed no significant associations with CAD in this sample.  Overall allele frequencies are 
comparable with previous studies from the region.  Some previous studies looking at different 
ethnic/regional groups of India have also failed to document association between IL-6 -174 
(G/C) (rs1800795) and CAD (Banerjee et al., 2009; Bhanushali and Das 2013). Hou et al. 
(2015) conducted a meta-analysis with 42 studies including 15,145 cases and 21,496 controls, 
and they reported that C allele of IL-6 -174 (G/C) was correlated with an increased risk of 
CAD in Caucasians (OR= 1.12, CI 1.03-1.22, p =0.007) but a similar effect was not observed 
in Indian populations (OR = 1.21, CI 0.74-1.99, p=0.45). There are some studies showing the 
opposite effect, with Phulukdaree et al. (2013) reporting that the presence of the IL-6 -174 
(G/C)  C allele influences levels of IL6 and increases the risk of CAD in South African 
Indians. Elsaid et al. (2014) reported that the G allele of IL-6 -174 (G/C) is significantly 
associated with CAD (OR = 3.44, CI 2.26-5.23, p<0.0001) while a recent meta-analysis 
showed that the association between CAD and IL-6 -174 (G/C) polymorphism is only a mild 
one (OR =0.80, CI 0.65-0.98, p =0.034) (Yang et al., 2013).  
In case of IL-6 -597 (G/A) (rs1800797), no statistically significant genotypic or allelic 
association was observed in the present study. There are only limited studies on this locus 
with reference to CAD in literature and none on Indian populations. Sun et al (2014) also 
finding no significant association of this locus with CAD in a Chinese population. Overall 
control allele and genotype frequencies observed here are comparable to a large study on this 
locus (albeit different disease: leprosy) (Aggarwal et al 2011) but our results are significantly 
different from a diabetes study which reported a very high frequency of A allele (87%) in 
controls (Saxena et al 2014). Haplotype analysis of the two loci also did not reach statistical 
significance in any combination.  Further large scale investigations are required to clarify the 
possible role of IL-6 polymorphisms in CAD among Indian populations. 
IFN-ɣ +874 (T/A) locus is also not studied extensively within Indian populations (Garg et al 
2013). Overall our results are comparable with the Garg et al. (2013) study however we only 
observed Codominant and Overdominant models to be statistically significant and this 
significance was lost when adjustments were made for clinical parameters. This 
polymorphism significantly interacted with Age in patients, TG and VLDL in controls in one 
way ANOVA (Table 4).  
There are some limitations to our study which should be considered.  Firstly CAD patients 
and control subjects were recruited from only one hospital leading to some selection bias. 
However, the genotype distributions for controls of all loci except IFN-ɣ +874 (T/A) are in 
HWE, which gives confidence that it could be considered as being representative of the 
general population.  The relatively small sample size of our study may have limited the 
statistical power to find the association of these five polymorphisms in CAD risk. However, 
prior sample size calculations suggested a sample size of 130 patients and 130 controls was 
sufficient to achieve a large odds ratio of 1.75 and above with 80% power. 
Overall the results provided here show that polymorphisms in TNF-α -308 (G/A) and TNF-β 
+252 (A/G) loci enhance the risk of heart disease in a North Indian population. These 
polymorphisms along with IFN-ɣ +874 (T/A) should be analysed in other Indian populations 
to confirm their role in CAD and other cardio metabolic diseases.  
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Table 1: Baseline characteristics of CAD patients and controls 
Variable CONTROL 
(n=137),  
Mean ± SD 
Or (n,  and % 
for categorical 
variables) 
PATIENTS 
(n=144) 
Mean±SD Or (n 
and % for 
categorical 
variables) 
T-test/ 
Chi-Square Test 
P value 
Age 45.02 ±14.46 49.51±11.06 -2.910 0.004* 
Sex,   
Male:  
Female  
 
111(81%) 
26 (19%) 
 
125(87%) 
19(13%) 
 
1.75 (1df) 
 
0.186 
Diet  
Veg:  
Non Veg 
 
65 (47%): 
72 (53%) 
 
60 (42%) 
84 (58%) 
 
0.95 (1df) 
 
0.330 
Smoking 
Non-smoker 
Smoker 
 
61 (44%) 
76 (56%) 
 
49 (34%) 
95 (66%) 
 
3.25 (1df) 
 
0.072 
TC 132.76±34.38 182.32±106.03 -5.322 <0.001* 
TG 145.64±66.03 208.01±109.45 -5.816 <0.001* 
HDL 23.40±7.29 29.74±12.37 -5.261 <0.001* 
LDL 80.71±27.25 106.37±42.94 -5.934 <0.001* 
VLDL 30.08±13.46 42.79±18.04 -6.61 <0.001* 
APOB 108.76±45.784 153.50±43.46 -8.394 <0.001* 
 
* =Statistically significant at 5% level. 
 
Table 2: Genotype, allele frequencies, Odds ratios and adjustments for various models for the studied SNPs among CAD patients 
Model Genotype/ 
Allele 
Control No, (%) 
 
N=136 
Patients 
No, (%) 
N=143 
Crude OR P value Age, Sex, TC, TG, 
HDL, VLDL, APOB, 
Smoking  and Diet 
Adjusted OR 
P value 
TNFα -308 (G/A), rs1800629 
 GG 131 (96.3) 118 (82.5)     
 AG 5 (3.7) 24 (16.7)     
 AA 0 (0.0) 1 (0.8)     
HWE P value  0.82 0.79     
Allele frequency *G 0.98 (±0.001) 0.91 (±0.02)     
 *A 0.02 (±0.001) 0.09 (±0.02)     
Co-dominant (AG vs. GG)    5.3 (2.0-14.4) <0.001 5.5 (1.7-17.3) 0.005 
Co-dominant (AA vs. GG)    NA  NA  
Dominant (AA+AG vs.GG)    5.5(2.1-15.0) <0.001 5.7 (1.8-17.8) 0.001 
Recessive (A/A vs. AG+GG)    NA  NA  
Over-dominant (AG vs. GG+AA)    5.3(1.9-14.3) <0.001 5.5 (1.7-17.3) 0.002 
Log-additive    5.4 (2.0-14.5) <0.001 5.6 (1.8-17.4) 0.001 
TNFβ +252 (A/G), rs909253 
 AA 107 (79.3) 68 (48.3)     
 AG 24 (17.8) 61 (43.2)     
 GG 4 (2.9) 12 (8.5)     
HWE-P value  0.08 0.68     
Allele frequency *A 0.88 (±0.02) 0.70 (±0.03)     
 *G 0.12 (±0.02) 0.30 (±0.03)     
Co-dominant (AG vs. AA)    4.0 (2.3-7.0) <0.001 4.6 (2.1-9.8) <0.001 
Co-dominant (GG vs. AA)    4.7 (1.5-15.2) <0.001 6.3 (1.5-25.9) <0.001 
Dominant (GG+AG vs. AA)    4.1 (2.4-7.1) <0.001 4.9 (2.4-9.9) <0.001 
Recessive (GG vs. AG+AA)    3.0 (1.0-9.6) 0.05 4.3 (1.1-17.6) 0.03 
Overdominant (AG vs. AA+GG)    3.5 (2.0-6.1) <0.001 4.0 (1.9-8.4) 0.002 
Log-additive    3.1 (2.0-4.9) <0.001 3.4 (1.9-6.0) <0.001 
IL6 -174 (G/C),  rs1800795 
 GG 91 (69.5) 105 (76.1)     
 GC 39 (29.8) 32 (23.2)     
 CC 1 (0.7) 1 (0.7)     
HWE-P value  0.14 0.35     
 Allele frequency *G 0.84 (±0.02) 0.88 (±0.02)     
 *C 0.16 (±0.02) 0.12 (±0.02)     
Co-dominant (CG vs. GG)    0.7(0.4-1.2) 0.5 0.5 (0.2-1.1) 0.2 
Co-dominant  (CC vs. GG)    0.9 (0.1-14.1) 0.5 0.8 (0.1-1 0.2 
Dominant (CC+CG vs. GG)    0.7 (0.4-1.2) 0.2 0.5(0.3-1.1) 0.1 
Recessive (CC vs. CG+GG)    0.9(0.1-15.3) 1.0 1.0(0.1-17.2) 0.1 
Overdominant (CG vs. GG+CC)    0.7(0.4-1.2) 0.2 0.5 (0.3-1.1) 0.1 
Log-additive    0.7(0.5-1.3) 0.2 0.6(0.3-1.1) 0.1 
IL6 -597 (G/A),  rs1800797 
 GG 98 (76.6) 104 (76.4)     
 AG 29 (22.6) 30 (22.1)     
 AA 1 (0.8) 2 (1.5)     
HWE-P value  0.47 0.85     
Allele frequency *G 0.88 (±0.02) 0.88 (±0.02)     
 *A 0.12 (±0.02) 0.12 (±0.02)     
Co-dominant (AG vs. AA)    0.5 (0.1-6.0) 0.9 1.0 (0.1-16.7) 1.0 
Co-dominant (AA vs. GG)    0.5 (0.1-5.9) 0.9 1.0 (0.1-16.5) 0.9 
Dominant (GG+AG vs. AA)    0.5 (0.1-5.9) 0.6 1.02 (0.1-16.4) 0.9 
Recessive (GG vs. AG+AA)    0.9 (0.6-1.8) 0.9 1.0 (0.6-1.8) 0.9 
Overdominant (AG vs. AA+GG)    1.0 (0.5-1.7) 0.9 1.0 (0.6-1.8) 0.9 
Log-additive    1.0 (0.6-1.6) 0.9 1.0 (0.6-1.7) 0.9 
IFNγ +874 (T/A),  rs2430561 
 AA 60 (45.8) 49 (35.2)     
 AT 44 (33.6) 65 (46.8)     
 TT 27 (20.6) 25 (18.0)     
HWE-P value  0.001* 0.63     
Allele frequency *A 0.63 (±0.03) 0.59 (±0.03)     
 *T 0.37 (±0.03) 0.41 (±0.03)     
Co-dominant (AT vs. AA)    1.8(1.0-3.1) 0.1 1.5(0.7-2.9) 0.6 
Co-dominant (TT vs. AA)    1.1(0.6-2.2) 0.1 1.06(0.5-2.5) 0.6 
Dominant (TT+AT vs. AA)    1.5 (0.9-2.5) 0.1 1.30 (0.7-2.5) 0.4 
Recessive (TT vs. AT+TT)    0.8 (0.5-1.5) 0.6 0.9 (0.4-1.9) 0.8 
Over-dominant (AT vs. AA+TT)    1.7 (1.1-2.8) 0.03 1.4 (0.7-2.7) 0.3 
Log-additive    1.1(0.8-1.6) 0.4 1.1(0.7-1.6) 0.7 
Table 3: Haplotype analysis of TNF-α (-308 A/G), TNF-β (+252 A/G) and IL-6 (-174 G/C; -597 G/A) polymorphisms 
 
 
Haplotype Overall 
Frequency 
Control 
Frequency 
Patients 
Frequency 
Crude OR P value Age, Sex, TC, TG, HDL, 
VLDL, APOB, Smoking  
and Diet Adjusted OR 
P value 
TNF-α (-308 A/G) –TNF-β (+252 A/G) 
GA 0.782 0.878 0.697 1.0 (ref)  1.0 (ref)  
GG 0.159 0.104 0.212 2.5(1.5-4.1) <0.001 2.6 (1.4-5.0) 0.003 
AG 0.053 0.014 0.093 7.8 (2.6-24.0) <0.001 8.5(2.2-33.35) 0.002 
AA 0.002 0.004 0.000 NA  NA  
Global Haplotype association P value     <0.001  <0.001 
D´ 0.95       
r 0.45       
P value <0.001       
IL-6 -174 (G/C) – IL-6 -597 (G/A ) 
GG 0.849 0.847 0.851 1.0 (ref)  1.0 (ref)  
CA 0.113 0.121 0.105 0.8(0.5-1.4) 0.4 0.7(0.3-1.3) 0.3 
CG 0.026 0.032 0.020 0.6 (0.2-1.9) 0.4 0.7 (0.2-2.9) 0.6 
GA 0.012 0.0 0.024 NA  NA  
Global Haplotype association P value     0.02  0.26 
D’ 0.89       
r 0.83       
P value <0.001       
Table 4: One Way ANOVA tests for interaction of genotypes with conventional risk factors 
 Mean+SD Mean+SD P-value 
 TNF-α (-308 G/A) TNF-β (+252 A/G) IFN-γ (+874 T/A) IL-6 (-174 G/C) IL-6 (-597G/A) 
 Patients Controls Patients Controls Patients Controls Patients Controls Patients Controls Patients Controls 
Age 49.51±11.06 45.02 ±14.46 0.68 0.37 0.65 0.17 0.01* 0.84 0.40 0.21 0.41 0.17 
TC 182.32±106.03 132.76±34.38 0.65 0.25 0.86 0.08 0.56 0.48 0.21 0.02* 0.28 0.02* 
TG 208.01±109.45 145.64±66.03 0.79 0.41 0.99 0.42 0.79 0.02* 0.46 0.78 0.14 0.74 
HDL 29.74±12.37 23.40±7.29 0.71 0.33 0.14 0.16 0.74 0.49 0.18 0.05* 0.25 0.04 
LDL 106.37±42.94 80.71±27.25 0.56 0.23 0.37 0.16 0.14 0.91 0.69 0.02* 0.95 0.02 
VLDL 42.79±18.04 30.08±13.46 0.12 0.12 0.46 0.83 0.24 0.05* 0.10 0.94 0.01* 0.94 
APOB 153.50±43.46 108.76±45.78 0.67 0.67 0.91 0.97 0.92 0.70 0.97 0.09 0.41 0.05 
       Post Hoc 
tests 
Age: TT 
vs. AT 
=0.03 
And AT 
vs AA 
=0.04 
Post Hoc 
tests 
TG: TT 
vs. AT 
=0.047 
And TT 
vs. AA 
=0.024. 
VLDL: 
TT vs. 
AA =0.04 
    
* = Statistically significant at 5% level 
